AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20407392 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational and behavioral interventions
Number of subjects: 0
Study 20407392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20016688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granitic sand surfacing
Number of subjects: 15074
Study 20016688 — intervention group
Group type: COMPARATOR
Intervention: Engineered wood fibre surfacing (Fibar)
Number of subjects: 15074
Study 20016688 — intervention group
Group type: EXPERIMENTAL
Intervention: Granitic sand surfacing (all schools)
Number of subjects: 15074
Study 20016688 — intervention group
Group type: COMPARATOR
Intervention: Engineered wood fibre surfacing (Fibar) (all schools)
Number of subjects: 15074
Study 17679633 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (n = 105)
Number of subjects: 206
Study 17679633 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 101)
Number of subjects: 206
Study 15086170 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic clipping
Number of subjects: 61
Study 15086170 — intervention group
Group type: COMPARATOR
Intervention: Polidocanol injection therapy
Number of subjects: 61
Study 12438291 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 30 mg/d
Number of subjects: 157
Study 12438291 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 100 mg/d
Number of subjects: 157
Study 12438291 — intervention group
Group type: EXPERIMENTAL
Intervention: Darusentan 300 mg/d
Number of subjects: 157
Study 12438291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 10520920 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye alone (B)
Number of subjects: 92
Study 10520920 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue dye plus radioactivity (B+R)
Number of subjects: 92
Study 10520920 — intervention group
Group type: COMPARATOR
Intervention: Needle localization (B)
Number of subjects: 92
Study 10520920 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (B and B+R combined)
Number of subjects: 92
Study 10520920 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 92
Study 10520920 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing SN identification
Number of subjects: 92
Study 7574459 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon beta‐1b (alternate-day injections)
Number of subjects: 107
Study 7574459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 2251340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 48
Study 2251340 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 48
Study 2251340 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 48
Study 2251340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6990950 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 40
Study 6990950 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.125 mg
Number of subjects: 40
Study 31929100 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVI (balloon-expandable transcatheter valve into the inferior vena cava)
Number of subjects: 28
Study 31929100 — intervention group
Group type: COMPARATOR
Intervention: OMT (optimal medical therapy)
Number of subjects: 28
Study 30414864 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 1 mg
Number of subjects: 62
Study 30414864 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282 3 mg
Number of subjects: 62
Study 30414864 — intervention group
Group type: EXPERIMENTAL
Intervention: NGM282
Number of subjects: 62
Study 30414864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 28954530 — intervention group
Group type: EXPERIMENTAL
Intervention: software-supplemented e-Parenting Program (ePP)
Number of subjects: 413
Study 28954530 — intervention group
Group type: COMPARATOR
Intervention: services as usual (SAU)
Number of subjects: 413
Study 28954530 — intervention group
Group type: COMPARATOR
Intervention: community referral conditions
Number of subjects: 413
Study 26131781 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling group
Number of subjects: 60
Study 26131781 — intervention group
Group type: COMPARATOR
Intervention: Nonsling group
Number of subjects: 60
Study 24803435 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free paclitaxel-eluting stent (PF‐PES)
Number of subjects: 164
Study 24803435 — intervention group
Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stent (PB‐PES)
Number of subjects: 164
Study 22537028 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstructured, moderate to vigorous, before-school physical activity program (12 weeks, 3 days a week, 7:30-8:15 a.m.)
Number of subjects: 0
Study 22537028 — intervention group
Group type: COMPARATOR
Intervention: Unstructured, moderate to vigorous, before-school physical activity program
Number of subjects: 0
Study 19692630 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2000 mg daily, step-up fashion for 8 weeks)
Number of subjects: 8
Study 19692630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin administration during clamp
Number of subjects: 8
Study 19692630 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 8
Study 17302186 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid mixture
Number of subjects: 2
Study 17302186 — intervention group
Group type: COMPARATOR
Intervention: Antisymptomatic treatment alone
Number of subjects: 2
Study 15712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy after myringotomy
Number of subjects: 30
Study 15712725 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy
Number of subjects: 30
Study 11133370 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (600 mg every 24 h) plus indinavir (1000 mg every 8 h)
Number of subjects: 327
Study 11133370 — intervention group
Group type: COMPARATOR
Intervention: placebo (every 24 h) plus indinavir (800 mg every 8 h)
Number of subjects: 327
Study 9033248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush combined with colposcopically directed biopsies
Number of subjects: 180
Study 9033248 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical curettage combined with colposcopically directed biopsies
Number of subjects: 180
Study 9033248 — intervention group
Group type: COMPARATOR
Intervention: Endocervical curettage
Number of subjects: 180
Study 8117053 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg + Hydrochlorothiazide 12.5 mg (L/HCTZ)
Number of subjects: 20
Study 8117053 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + Hydrochlorothiazide 25 mg (C/HCTZ)
Number of subjects: 20
Study 2942416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg ipratropium powder
Number of subjects: 10
Study 2942416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ipratropium powder
Number of subjects: 10
Study 2942416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ipratropium powder
Number of subjects: 10
Study 2942416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30875607 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS training (eight weekly 40-min sessions)
Number of subjects: 131
Study 30875607 — intervention group
Group type: EXPERIMENTAL
Intervention: FMS training (DCD-FMS group)
Number of subjects: 131
Study 30875607 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical education lessons (control group)
Number of subjects: 131
Study 28935268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20mg)
Number of subjects: 0
Study 28935268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26343743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTi) followed by Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 26343743 — intervention group
Group type: COMPARATOR
Intervention: Attention control followed by Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 24229753 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine plus sertraline
Number of subjects: 259
Study 24229753 — intervention group
Group type: COMPARATOR
Intervention: olanzapine plus placebo
Number of subjects: 259
Study 21557757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribose cross-linked collagen membranes (RCLM)
Number of subjects: 37
Study 21557757 — intervention group
Group type: COMPARATOR
Intervention: Non-cross-linked membranes (Control)
Number of subjects: 37
Study 21557757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 37
Study 19520908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg twice a day
Number of subjects: 23
Study 19520908 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 10 mg twice a day
Number of subjects: 23
Study 19520908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 17563395 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d)
Number of subjects: 979
Study 17563395 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 or 30 mg/d)
Number of subjects: 979
Study 15060689 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (50 mg/kg, not exceeding 1 g)
Number of subjects: 110
Study 15060689 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of amoxicillin-clavulanate (45 mg/kg/day, in 3 divided doses)
Number of subjects: 110
Study 15060689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 110
Study 15060689 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 110
Study 11574373 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.0625% bupivacaine with fentanyl (3 microg/mL)
Number of subjects: 51
Study 11574373 — intervention group
Group type: COMPARATOR
Intervention: Preservative‐free saline infusion
Number of subjects: 51
Study 9562227 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 ml)
Number of subjects: 8
Study 9562227 — intervention group
Group type: COMPARATOR
Intervention: Water (250 ml)
Number of subjects: 8
Study 7826431 — intervention group
Group type: EXPERIMENTAL
Intervention: Music by J. Strauss
Number of subjects: 20
Study 7826431 — intervention group
Group type: EXPERIMENTAL
Intervention: Music by H. W. Henze
Number of subjects: 20
Study 2969860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA, 50 mg/day orally)
Number of subjects: 10
Study 2969860 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Trp6 LHRH (3 mg i.m. once a month)
Number of subjects: 10
Study 2969860 — intervention group
Group type: COMPARATOR
Intervention: LHRH-A
Number of subjects: 10
Study 1969436 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine detergent solution
Number of subjects: 20
Study 1969436 — intervention group
Group type: COMPARATOR
Intervention: 2% triclosan detergent solution
Number of subjects: 20
Study 1969436 — intervention group
Group type: COMPARATOR
Intervention: non-medicated soap
Number of subjects: 20
Study 138480 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FUDR via hepatic artery infusion (HAI)
Number of subjects: 21
Study 31641831 — intervention group
Group type: EXPERIMENTAL
Intervention: Public responsibility message
Number of subjects: 448
Study 31641831 — intervention group
Group type: EXPERIMENTAL
Intervention: Media responsibility message
Number of subjects: 448
Study 31641831 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 448
Study 31432915 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge guidance and telephone follow-up intervention
Number of subjects: 201
Study 31432915 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 201
Study 27760884 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-caliber coils
Number of subjects: 70
Study 27760884 — intervention group
Group type: COMPARATOR
Intervention: 10-caliber coils
Number of subjects: 70
Study 26305054 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping applied over the deltoid muscle with tension
Number of subjects: 24
Study 26305054 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 24
Study 26305054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham (Kinesio taping applied over deltoid without tension)
Number of subjects: 24
Study 22572414 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS) to the left intraparietal sulcus
Number of subjects: 0
Study 22572414 — intervention group
Group type: COMPARATOR
Intervention: Theta-burst stimulation (TBS) to the right parietal region
Number of subjects: 0
Study 21649590 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release nicotinic acid 1500 mg
Number of subjects: 60
Study 21649590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 60
Study 19347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 368
Study 19347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 10 mg
Number of subjects: 368
Study 19347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan and Ramipril
Number of subjects: 368
Study 19347385 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with a history of coronary artery disease or myocardial infarction
Number of subjects: 368
Study 17050586 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg/day
Number of subjects: 633
Study 17050586 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg/day
Number of subjects: 633
Study 17050586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 633
Study 14692888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 1455
Study 14692888 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Tract Infection (UTI)
Number of subjects: 1455
Study 11558483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (1 hour in 100% oxygen at 1.75 ATA)
Number of subjects: 111
Study 11558483 — intervention group
Group type: COMPARATOR
Intervention: Slightly pressurised room air (1 hour at 1.3 ATA)
Number of subjects: 111
Study 11558483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 111
Study 11558483 — intervention group
Group type: COMPARATOR
Intervention: Slightly pressurised room air
Number of subjects: 111
Study 9025012 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment for metabolic control
Number of subjects: 20
Study 9025012 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 20
Study 8337029 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-T vaccine
Number of subjects: 10317
Study 8337029 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B control vaccine
Number of subjects: 10317
Study 3773141 — intervention group
Group type: EXPERIMENTAL
Intervention: High Poly diet
Number of subjects: 9
Study 3773141 — intervention group
Group type: COMPARATOR
Intervention: AHA phase I diet
Number of subjects: 9
Study 3773141 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA phase III diet
Number of subjects: 9
Study 28958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report indices SR-1/4MILE
Number of subjects: 0
Study 28958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report indices SR-BLOCKS
Number of subjects: 0
Study 28958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective MMD
Number of subjects: 0
Study 28958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report indices SR-STAIRS
Number of subjects: 0
Study 28958023 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SR-STAIRS with SR-1/4MILE or SR-BLOCKS
Number of subjects: 0
Study 29076219 — intervention group
Group type: EXPERIMENTAL
Intervention: CaCl2
Number of subjects: 40
Study 29076219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate (ZG)
Number of subjects: 40
Study 29076219 — intervention group
Group type: EXPERIMENTAL
Intervention: CaCl2 + ZG
Number of subjects: 40
Study 29076219 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 29076219 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (CaCl2, ZG, CaCl2 + ZG, Saline)
Number of subjects: 40
Study 26288364 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin
Number of subjects: 1444
Study 26288364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1444
Study 24128148 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving methadone‐maintenance treatment for opioid dependence
Number of subjects: 34
Study 24128148 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study 21419395 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (Group I)
Number of subjects: 176
Study 21419395 — intervention group
Group type: COMPARATOR
Intervention: Observation only (Group II)
Number of subjects: 176
Study 17936278 — intervention group
Group type: EXPERIMENTAL
Intervention: Determination of P(ET)CO(2) once daily
Number of subjects: 160
Study 17936278 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of E(2) or P
Number of subjects: 160
Study 16310886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 on days 1 and 8 + Carboplatin AUC 6 mg/(mLmin) on day 1 (GC)
Number of subjects: 100
Study 16310886 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine 30 mg/m2 weekly + Cisplatin 80 mg/m2 on day 1 (VP)
Number of subjects: 100
Study 12024077 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (Group EA)
Number of subjects: 210
Study 12024077 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia integrated with mild general anaesthesia (IA)
Number of subjects: 210
Study 12024077 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 210
Study 10375806 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (Cic) 100 mg alone
Number of subjects: 7
Study 10375806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (Cic) 100 mg with Simvastatin (Sim) 10 mg
Number of subjects: 7
Study 7818264 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline plus L-dopa-carbidopa
Number of subjects: 82
Study 7818264 — intervention group
Group type: COMPARATOR
Intervention: L-dopa-carbidopa alone
Number of subjects: 82
Study 2269136 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall interval of three months for patients with partial dentures
Number of subjects: 0
Study 2269136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive aftercare
Number of subjects: 0
Study 346488 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli H‐10407 (CFA-positive strain) at a dose of 1 X 10(8)
Number of subjects: 13
Study 346488 — intervention group
Group type: COMPARATOR
Intervention: E. coli H‐10407‐P (CFA-negative strain) at a dose of 1 X 10(8)
Number of subjects: 13
Study 346488 — intervention group
Group type: EXPERIMENTAL
Intervention: E. coli H‐10407 (CFA-positive strain)
Number of subjects: 13
Study 346488 — intervention group
Group type: COMPARATOR
Intervention: E. coli H‐10407‐P (CFA-negative strain)
Number of subjects: 13
Study 29941505 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive perventricular closure
Number of subjects: 200
Study 29941505 — intervention group
Group type: COMPARATOR
Intervention: Standard open surgical closure
Number of subjects: 200
Study 26886210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes
Number of subjects: 27
Study 26886210 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose e-cigarettes
Number of subjects: 27
Study 25214238 — intervention group
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 (via EORTC-8D)
Number of subjects: 0
Study 25214238 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36v2 (via SF-6D)
Number of subjects: 0
Study 22744651 — intervention group
Group type: EXPERIMENTAL
Intervention: A0001 (α‐tocopheryl quinone; EPI‐A0001)
Number of subjects: 31
Study 22744651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 20211530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered 1h before retention testing
Number of subjects: 20
Study 20211530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17337198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-bypass (Dideco ECC.O)
Number of subjects: 60
Study 17337198 — intervention group
Group type: COMPARATOR
Intervention: Conventional system (Dideco 903 Avant)
Number of subjects: 60
Study 15698525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral vaporisation of the prostate (TUVP)
Number of subjects: 0
Study 15698525 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 15698525 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 0
Study 15698525 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 0
Study 15698525 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP and TUVP
Number of subjects: 0
Study 12174030 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg intravenous methylprednisolone in the morning
Number of subjects: 8
Study 12174030 — intervention group
Group type: COMPARATOR
Intervention: 16 mg intravenous methylprednisolone in the morning and 16 mg in the evening
Number of subjects: 8
Study 9651462 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperpronation
Number of subjects: 90
Study 9651462 — intervention group
Group type: COMPARATOR
Intervention: Supination
Number of subjects: 90
Study 9651462 — intervention group
Group type: COMPARATOR
Intervention: Crossover from Supination to Hyperpronation
Number of subjects: 90
Study 7843746 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV‐116 (4 mg PO daily)
Number of subjects: 27
Study 7843746 — intervention group
Group type: EXPERIMENTAL
Intervention: TCV‐116 (1, 2, or 4 mg PO daily)
Number of subjects: 27
Study 7843746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 1977012 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) insertion
Number of subjects: 110